Bradley Merrill Thompson, a Member of the Firm in the Health Care and Life Sciences practice, in the firm’s Washington, DC, office, was quoted in Inside Health Policy, in “FDA Lays Out Possible Risk-Based Approach to LDT Oversight,” by Nicholas Florko. (Read the full version – subscription required.)
Following is an excerpt:
Brad Thompson, attorney at Epstein, Becker & Green, praised FDA’s call for greater transparency around LDTs.
“Embedded in the proposal is a plea for greater transparency. Many of us like the free market, and the free market works best when there is a transparency of information… [O]ne of the most problematic aspects of the current system is that the evidence supporting many of these LDTs is opaque at best. It’s impossible to make intelligent decisions without good information,” Thompson wrote to Inside Health Policy.
Thompson praised the FDA paper for its understanding of the various oversight roles by different agencies, and said it would make it harder for laboratories to complain to Congress.